Bod Science (ASX:BOD) 3-Year RORE % : -64.13% (As of Jun. 2025)


ASX:BOD Bod Science Ltd ASX:BOD
12 GF Score
Price A$0.02
GF Value A$0.04
! 3 Warning Signs
View Full Analysis

What is Bod Science 3-Year RORE %?

Bod Science ASX:BOD 12 3-Year RORE % is -64.13 as of Jun. 2025. GuruFocus rates ASX:BOD with a GF Score™ of 12/100 and a GF Value™ of A$0.04. The stock has 3 warning signs investors should review.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Bod Science's 3-Year RORE % for the quarter that ended in Jun. 2025 was -64.13%.

The industry rank for Bod Science's 3-Year RORE % or its related term are showing as below:

ASX:BOD's 3-Year RORE % is not ranked
in the Drug Manufacturers industry.
Industry Median: 3.09 vs ASX:BOD: -64.13

Bod Science  (ASX:BOD) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Bod Science 3-Year RORE % Related Terms


Bod Science 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Bod Science's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bod Science 3-Year RORE % Chart

Bod Science Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only -34.45 -2.07 10.07 -9.03 -64.13

Bod Science Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.07 11.70 -9.03 -43.55 -64.13

ASX:BOD vs ZTS: 3-Year RORE % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Bod Science's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bod Science 3-Year RORE % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bod Science's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Bod Science's 3-Year RORE % falls into.


ASX:BOD
12GF Score
Bod Science Ltd ASX:BOD
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bod Science 3-Year RORE % Calculation

Bod Science's 3-Year RORE % for the quarter that ended in Jun. 2025 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( 0.002--0.057 )/( -0.092-0 )
=0.059/-0.092
=-64.13 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2025 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of -64.13 mean?
Bod Science (ASX:BOD) has a 3-Year RORE % of -64.13 as of Jun. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Bod Science and its competitors.
Is Bod Science's 3-Year RORE % too high?
Bod Science's current 3-Year RORE % is -64.13. Overall, Bod Science has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bod Science's 3-Year RORE % compare to ZTS?
Bod Science's 3-Year RORE % of -64.13 can be compared against companies in the Drug Manufacturers industry. The industry median 3-Year RORE % is 3.09. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Drug Manufacturers company?
The median 3-Year RORE % among Drug Manufacturers companies is 3.09, based on 937 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Bod Science and its competitors. For the Drug Manufacturers industry, the median 3-Year RORE % is 3.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bod Science's current 3-Year RORE % is -64.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bod Science stock overvalued right now?
Bod Science (ASX:BOD) has a current 3-Year RORE % of -64.13. The stock's GF Value™ is A$0.04, compared to a current price of A$0.02 — trading 40% below its estimated fair value. The current 3-Year RORE % is -64.13. Bod Science's overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Bod Science (ASX:BOD), the current 3-Year RORE % is -64.13 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bod Science (ASX:BOD) Overvalued in 2026?

Based on GuruFocus' analysis, Bod Science stock appears to be undervalued. The current stock price of A$0.02 is trading 40% below its estimated GF Value™ of A$0.04.

Key valuation signals for ASX:BOD:

  • 3-Year RORE %: -64.13
  • GF Value™: A$0.04 vs. price of A$0.02 (40% below fair value)
  • GF Score™: 12/100 with 3 warning signs

No single metric tells the full story. See the ASX:BOD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bod Science Business Description

Address C/- Rodgers Reidy, 210 Clarence Street, Level 12, Sydney, NSW, AUS, 2000
Bod Science Ltd is a healthcare company combining the power of nature and science to deliver cannabis-derived health and skincare products, designed to improve lives and transform the medicinal cannabis, CBD, and hemp market. The firm is focused on cannabis drug development and products. The company is focused on progressing Research and Development and a defined clinical trial pathway to commercialize and deliver premium, scientifically trusted products for the consumer and medical markets. It earned it profits and sales revenue from Australia even though have segment in UK, Europe and USA.
12GF Score

Get the complete analysis for ASX:BOD

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.02
Price
A$0.04
GF Value